Article
Pharmacokinetics of venlafaxine extended release 75 mg and desvenlafaxine 50 mg in healthy CYP2D6 extensive and poor metabolizers: a randomized, open-label, two-period, parallel-group, crossover study.
Clinical drug investigation - 1 Jan 2011
Nichols Alice I, Focht Kristen, Jiang Qin, Preskorn Sheldon H, Kane Cecelia P
Abstract excerpt
BACKGROUND: Genetically driven variations in the level of cytochrome P450 (CYP) 2D6 metabolic activity have been shown to significantly affect the pharmacokinetic behaviour of medications that are substrates of this enzyme. OBJECTIVE: To evaluate the impact of CYP2D6 extensive metabolizer (EM) and poor metabolizer (PM) phenotypes on the pharmacokinetics of single doses of venlafaxine extended release (ER) and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.